The Spac story departs from the script
Immunovant, the poster child for the hot new biotech flotation vehicle, might soon go private again.
Sumitomo takes out Urovant, and Myovant beckons
With one portfolio asset rejected by the FDA and another looking dicey, Sumitomo looks pretty reliant on Vibegron.
The Covid-19 vaccine battle just got interesting
A patent claim against Arbutus is thrown out, threatening parts of Moderna’s mRNA technology – including its Covid-19 vaccine.
Myovant socks it to Orilissa
Two years after Abbvie’s disappointing launch of Orilissa Myovant hails the development of something much better.
Relugolix gets a Hero’s welcome in prostate cancer
The Hero study gives Myovant an opportunity to change the way hormone-sensitive prostate cancer is treated.
Horizon looks for a new growth driver
The company plans to make the most of its head start with the Graves’ disease project teprotumumab, which is forecast to become its biggest product.
UCB goes to Ra for a complementary approach
The $2bn takeout of Ra Pharmaceuticals provides solace for investors bemoaning the biotech market’s poor performance.
Sumitomo bets on Roivant to solve its patent expiry woes
The Japanese company is to hand across $3bn to Roivant for various subsidiaries that hold an eclectic portfolio of assets.
